News & Events about Marinus Pharmaceuticals Inc.
Business Wire
3 months ago
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering price of $4.75 per...
Business Wire
3 months ago
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a revenue interest financing agreement with Sagard Healthcare Partners for a total of $32.5 million...
Business Wire
6 months ago
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to seven new employees. The Compensation Committee of the Board of Directors of Marinus approved...
Business Wire
8 months ago
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following investor and medical conferences in May and June: Citi Biotech Virtual...